Literature DB >> 21724913

Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina.

Min Zhao1, Elodie Bousquet, Fatemeh Valamanesh, Nicolette Farman, Jean-Claude Jeanny, Frederic Jaisser, Francine F Behar-Cohen.   

Abstract

PURPOSE: Glucocorticoids are used to treat macular edema, although the mechanisms underlying this effect remain largely unknown. The authors have evaluated in the normal and endotoxin-induced uveitis (EIU) rats, the effects of dexamethasone (dex) and triamcinolone acetonide (TA) on potassium channel Kir4.1 and aquaporin-4 (AQP4), the two main retinal Müller glial (RMG) channels controlling retinal fluid movement.
METHODS: Clinical as well as relatively low doses of dex and TA were injected in the vitreous of normal rats to evaluate their influence on Kir4.1 and AQP4 expression 24 hours later. The dose-dependent effects of the two glucocorticoids were investigated using rat neuroretinal organotypic cultures. EIU was induced by footpad lipopolysaccharide injection, without or with 100 nM intraocular dex or TA. Glucocorticoid receptor and channel expression levels were measured by quantitative PCR, Western blot, and immunohistochemistry.
RESULTS: The authors found that dex and TA exert distinct and specific channel regulations at 24 hours after intravitreous injection. Dex selectively upregulated Kir4.1 (not AQP4) in healthy and inflamed retinas, whereas TA induced AQP4 (not Kir4.1) downregulation in normal retina and upregulation in EIU. The lower concentration (100 nM) efficiently regulated the channels. Moreover, in EIU, an inflammatory condition, the glucocorticoid receptor was downregulated in the retina, which was prevented by intravitreous injections of the low concentration of dex or TA.
CONCLUSIONS: The results show that dex and TA are far from being equivalent to modulate RMG channels. Furthermore, the authors suggest that low doses of glucocorticoids may have antiedematous effects on the retina with reduced toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724913     DOI: 10.1167/iovs.11-7675

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

Review 1.  Sustained-release steroids for the treatment of diabetic macular edema.

Authors:  Alejandra Daruich; Alexandre Matet; Francine Behar-Cohen
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

2.  Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy.

Authors:  Lalit P Singh
Journal:  J Clin Exp Ophthalmol       Date:  2013-08-05

Review 3.  The role of glial-specific Kir4.1 in normal and pathological states of the CNS.

Authors:  Sinifunanya E Nwaobi; Vishnu A Cuddapah; Kelsey C Patterson; Anita C Randolph; Michelle L Olsen
Journal:  Acta Neuropathol       Date:  2016-03-09       Impact factor: 17.088

4.  Inhibition of Kir4.1 potassium channels by quinacrine.

Authors:  Leticia G Marmolejo-Murillo; Iván A Aréchiga-Figueroa; Meng Cui; Eloy G Moreno-Galindo; Ricardo A Navarro-Polanco; José A Sánchez-Chapula; Tania Ferrer; Aldo A Rodríguez-Menchaca
Journal:  Brain Res       Date:  2017-03-11       Impact factor: 3.252

Review 5.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

Review 6.  Aquaporins in the eye: expression, function, and roles in ocular disease.

Authors:  Kevin L Schey; Zhen Wang; Jamie L Wenke; Ying Qi
Journal:  Biochim Biophys Acta       Date:  2013-10-31

Review 7.  Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

Authors:  Francesco Sartini; Michele Figus; Marco Nardi; Giamberto Casini; Chiara Posarelli
Journal:  Eye (Lond)       Date:  2019-03-01       Impact factor: 3.775

8.  The Application of Methylprednisolone Nanoscale Zirconium-Porphyrin Metal-Organic Framework (MPS-NPMOF) in the Treatment of Photoreceptor Degeneration.

Authors:  Yajie Wang; Wei Liu; Bo Yuan; Xuebo Yin; Yiming Li; Zongjin Li; Jianlin Cui; Xiaoyong Yuan; Yuhao Li
Journal:  Int J Nanomedicine       Date:  2019-12-10

9.  Retinal glycoprotein enrichment by concanavalin a enabled identification of novel membrane autoantigen synaptotagmin-1 in equine recurrent uveitis.

Authors:  Margarete E Swadzba; Stefanie M Hauck; Hassan Y Naim; Barbara Amann; Cornelia A Deeg
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

10.  Incidence of Paradoxical Neurosensory Detachment in Diabetic Eyes Undergoing Hemodialysis for End-Stage Renal Disease.

Authors:  Kshitiz Kumar; Santosh Balasubramaniam; Pallavi Raj; Amar Agarwal
Journal:  Cureus       Date:  2021-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.